{
  "symbol": "OCEAW",
  "company_name": "Ocean Biomedical Inc WT",
  "ir_website": "https://investors.oceanbiomedical.com/",
  "structured_data": [
    {
      "section_name": "Error Details",
      "links": [
        {
          "title": "ERR_HTTP2_PROTOCOL_ERROR",
          "url": "https://investors.oceanbiomedical.com",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb95651/themes/site/client_site_301/dist/images/medical_research_facility_interior_windows_gllass_white_bright.jpg)\n\n# Investor Relations\n\nOcean Biomedical is partnering with top tier researchers to accelerate new discoveries in the world of medicine, one powerful idea at a time.\n\n## Corporate Profile\n\nOcean Biomedical is building innovative partnerships with promising researchers and institutions. Together we identify medical discoveries that can change global health outcomes.\n\nWe deploy the funding and expertise to move new therapies efficiently from the laboratory to the clinic, to the world.\n\n[learn more](/corporate-profile)\n\n## Common Stock\n\nMinimum 15 minutes delayed. Source: LSEG\n\n  * [view stock](/stock-information/stock-quote-chart)\n\n\n\n## Press Releases\n\n01 Oct 2024\n\n##  [Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses](/news-releases/news-release-details/ocean-biomedical-inc-nasdaq-ocea-announces-publication-new-data)\n\nOcean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer , Glioblastoma, Prostate Cancer, Melanoma, and Breast Cancer Providence, RI , Oct. 01, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA ) announced \n\n27 Aug 2024\n\n##  [Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms](/news-releases/news-release-details/ocean-biomedical-inc-nasdaq-ocea-announces-patent-issued-pfgarp)\n\nProvidence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE, Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of malaria parasites, and their control of that mechanism. \n\n23 Aug 2024\n\n##  [Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q](/news-releases/news-release-details/ocean-biomedical-inc-announces-receipt-notice-nasdaq-regarding)\n\nPROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. ( NASDAQ : OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the \n\n[View All News](/news-events/press-releases \"View all releases\")\n\n## Latest Presentations\n\n[R&D Update: Malaria and Fibrosis Programs](https://www.youtube.com/watch?v=pQqawpFUvZ8)\n\n[view all presentations](/news-events/presentations-events)\n\n## Latest Events\n\nMore events are coming soon.\n\n![Ocean Biomedical, Inc.](/sites/g/files/knoqqb95651/themes/site/client_site_301/dist/images/logo.png)\n"
        }
      ]
    }
  ]
}